Image
Event
AMP Annual Meeting & Expo (Association for Molecular Pathology)
19-23 Nov 2024
Join us at the AMP Annual Meeting & Expo 2024
November 19 - 23, 2024
Vancouver, British Columbia (Canada)
Booth #1225
Corporate Workshop
Wednesday, November 20th
10:00 AM – 10:50 AM
Vancouver Convention Center, Level 2, Room 208 & 209
Title: The value of internalizing FDA- authorized tumor genomic profiling solutions for tissue and liquid biopsy
Description: Clinical NGS has advanced precision oncology, enabling physicians to identify actionable biomarkers in patients to aid in therapy selection. This workshop highlights the value of internalizing FDA-cleared tissue and an FDA authorized targeted liquid biopsy tumor profiling kitted solutions with best-in-class bioinformatics to help provide greater access to cancer patients worldwide. This workshop will also showcase our new FDA de novo authorized liquid biopsy kitted solution and examine the validation data included in the FDA submission. Lastly, there will be a panel discussion of active users who will discuss their point of view on the value of internalizing these solutions.
Featured Panelists
Dr. Ari Rao, MD, PhD
SVP of Pathology and Lab Medicine, and Pathology Chair
Baylor Scott & White
Image
Dr. Rachel Starks, MD, PhD
Director of Medical Laboratory
Sanford Health
Image
Dr. Chris Coldren, PhD
Sr. Scientific Director of Bioinformatics
PathGroup Labs
Innovation Spotlight Stage
Thursday, November 21st
12:40 PM – 1:10 PM
Innovation Spotlight Stage #2
Title: Enabling access to genomic profiling through the FDA- authorized decentralized liquid biopsy solution, PGDx elio™ plasma focus Dx
Description: Liquid biopsy next-generation sequencing assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable. Analytical validation an FDA authorized targeted 33-gene kitted assay, PGDx elio™ plasma focus Dx, has shown that detection of cancer-associated variants in ctDNA is highly specific, sensitive, reproducible and accurate.
Learn more about Labcorp Oncology's FDA authorized kitted tissue and liquid profiling solutions
Poster presentations:
| Session Date & Time | Presenting Author | Title | Details |
| Saturday, November 23 9:15AM–10:15AM PST | Sabi Pabla | Analytical validation of OmniSeq® INSIGHT whole exome sequencing assay to facilitate precision oncology through tumor-only testing in solid tumors. | Session Category: Solid Tumors Poster Board #ST021 |
| Saturday, November 23 9:15AM–10:15AM PST | Sabi Pabla | Analytical validation of OmniSeq® INSIGHT whole transcriptome sequencing assay to facilitate precision oncology through tumor-only testing in solid tumors. | Session Category: Solid Tumors Poster Board #ST023 |
| Saturday, November 23 9:15AM–10:15AM PST | Sabi Pabla | Validation of automated nucleic acid extraction using Covaris® Gen3 extraction methodology on the Assay-Ready Workstation. | Session Category: Technical Topics Poster Board #TT075 |
| Saturday, November 23 9:15AM–10:15AM PST | Ken Valkenburg | Enabling Access to Genomic Profiling Through Decentralized Liquid Biopsy Solution PGDx elio plasma focus Dx. | Session Category: Solid Tumors Poster Board #ST093 |
| Saturday, November 23 9:15AM–10:15AM PST | Michelle Green | Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers. | Session Category: Solid Tumors Poster Board #ST079 |
| Saturday, November 23 9:15AM–10:15AM PST | [External co-author] Ashutosh Vashisht | Optimizing genomic profiling: A comparative study of chromosomal microarray (CMA) and a 505-gene next-generation sequencing (NGS) panel for homologous recombination deficiency (HRD) phenotype assessment across diverse solid tumor types using NxClinical. | Session Category: Solid Tumors Poster Board #ST125 |
| Saturday, November 23 9:15AM–10:15AM PST | [External co-author] Ashutosh Vashisht | Precision Oncology: Identifying Clinically Relevant CNAs in Solid tumors using an Integrated Workflow of NGS and Bioinformatics. | Session Category: Solid Tumors Poster Board #ST129 |
Labcorp subject matter experts will be participating in the following discussions during the meeting.
Wednesday, November 20
11:00 – 11:50 AM
Vancouver Convention Center, Level 2, Rooms 212 & 213
Dr. Heidi Ko will be part of a panel discussion about the challenges and practice gaps affecting the implementation of precision oncology in clinical practice from the lens of an oncologist hosted by Illumina and Bayer.
Title: A Panel Discussion on Challenges and Practice Gaps Affecting Implementation of Oncology Precision Medicine
12:00 – 12:50 PM
Vancouver Convention Center, Level 1, Rooms118
Dr. Jennifer Dickey will be part of a panel discussion with other market leaders in the field of liquid biopsy. The panelists will talk through the challenges and opportunities to bring MRD to clinical practice and clinical trial management. This session will be hosted by Ultima Genetics
Title: Fireside Chat with Market Leaders in the Liquid Biopsy Field: Bringing MRD Testing to Clinical Practice with High-quality Large-scale Sequencing at Low Cost
4:00 – 4:50 PM
Vancouver Convention Center, Level 2, Rooms 208 & 209
Comprehensive Genomic Profiling (CGP) enables targeted therapy in oncology by identifying actionable mutations in solid tumors. Formalin-fixed paraffin-embedded (FFPE) tissues are challenging for high-quality nucleic acid extraction, crucial for sequencing. We present the Sonication STAR, an automated solution developed by Hamilton, Covaris, and Labcorp, enhancing FFPE sample processing for CGP. This method reduces 'quantity not sufficient' (QNS) samples, improves sequencing performance, and increases fully reported tumor profiles by 16%, offering cost savings, efficiency, and reduced re-extractions in CGP workflows.
Title: High Throughput Genomic Profiling of Solid Tumor FFPE Specimens with Fully Automated Extraction